AI-guided design of plectin-1-targeted <sup>68</sup>Ga-radiotracers reveals EP300-mediated membrane relocalization of plectin-1 in pancreatic ductal adenocarcinoma.
Authors
Affiliations (15)
Affiliations (15)
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China.
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China.
- Center for Biomedical Imaging, Fudan University, Shanghai, China.
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. [email protected].
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [email protected].
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. [email protected].
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China. [email protected].
- Center for Biomedical Imaging, Fudan University, Shanghai, China. [email protected].
- Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China. [email protected].
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [email protected].
- Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, China. [email protected].
- Key Laboratory of Nuclear Physics and Ion-beam Application (MOE), Fudan University, Shanghai, 200433, China. [email protected].
- Center for Biomedical Imaging, Fudan University, Shanghai, China. [email protected].
Abstract
Plectin-1 (PLEC) is a membrane-associated biomarker implicated in the progression of pancreatic ductal adenocarcinoma (PDAC) and is an attractive target for molecular imaging. However, peptide-based radiotracers targeting PLEC remain limited, and the mechanisms linking plectin-1 relocalization to aggressive biology have yet to be fully elucidated. In the present study, we performed stepwise in silico screening to identify membrane-associated metastatic drivers in PDAC. Then, we performed convolutional neural network-assisted docking to guide the design of <sup>68</sup>Ga-labeled NOTA-conjugated plectin-1-targeted monomeric (FZPN) and dimeric (FZPN-dimer) radiotracers. Radiochemical characterization, surface plasmon resonance, cellular uptake, blocking, pharmacokinetic, microPET/CT, biodistribution, and preliminary toxicity studies were then undertaken in PANC-1 models. Mechanistic studies assessed the subcellular localization of PLEC, its interaction with EP300, acetylation, and the functional role of lysine 1310 (K1310). PLEC emerged as the top membrane-enriched, metastasis-linked, and prognostically adverse candidate for PDAC. Analysis demonstrated that the [<sup>68</sup>Ga]Ga-NOTA-FZPN-dimer exhibited high affinity for PLEC, favorable hydrophilicity and stability, and significantly higher cellular uptake and tumor accumulation than the monomeric tracer, with receptor-specific blockade in vitro and in vivo. In PANC-1 xenografts, tumor uptake of the dimer reached 3.8 ± 0.5%ID/g at 30 min after injection and remained higher than that of the monomer at all imaging time points. Mechanistically, PDAC tissues exhibited membrane-enriched PLEC; EP300 interacted with PLEC, acetylation was increased in PDAC cells, and the deacetylation-mimetic PLEC-K1310R mutant redirected plectin-1 away from the plasma membrane and reduced cell migration. Collectively, our findings show that [<sup>68</sup>Ga]Ga-NOTA-FZPN-dimer represents a promising PLEC-targeted PET radiotracer for molecular imaging in PDAC. EP300-mediated acetylation at K1310 appears to drive the membrane relocalization of PLEC and promote the migration of tumor cells, providing biological support for PLEC-targeted imaging and a rationale for further translational development.